PuSH - Publikationsserver des Helmholtz Zentrums München

Yazgili, A.S. ; Ebstein, F.* ; Meiners, S.*

The proteasome activator PA200/PSME4: An emerging new player in health and disease.

Biomolecules 12:1150 (2022)
Verlagsversion DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Proteasomes comprise a family of proteasomal complexes essential for maintaining protein homeostasis. Accordingly, proteasomes represent promising therapeutic targets in multiple human diseases. Several proteasome inhibitors are approved for treating hematological cancers. However, their side effects impede their efficacy and broader therapeutic applications. Therefore, understanding the biology of the different proteasome complexes present in the cell is crucial for developing tailor-made inhibitors against specific proteasome complexes. Here, we will discuss the structure, biology, and function of the alternative Proteasome Activator 200 (PA200), also known as PSME4, and summarize the current evidence for its dysregulation in different human diseases. We hereby aim to stimulate research on this enigmatic proteasome regulator that has the potential to serve as a therapeutic target in cancer.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Korrespondenzautor
Schlagwörter Pa200 ; Psme4 ; Proteasome
ISSN (print) / ISBN 2218-273X
e-ISSN 2218-273X
Zeitschrift Biomolecules
Quellenangaben Band: 12, Heft: 8, Seiten: , Artikelnummer: 1150 Supplement: ,
Verlag MDPI
Verlagsort Basel
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Lung Health and Immunity (LHI)
Förderungen Bundesministerium für Bildung und Forschung
German Ministry of Research